Product news from the 05/23/06 News Brief

Share this article:
The FDA approved the first generic version Forest Laboratories’ Lexapro (escitalopram oxalate) to treat major depression, according to a posting on the agency’s Web site. The decision means that Ivax Corporation of Miami, a division of Israel’s Teva Pharmaceuticals, is the first company cleared to market a generic Lexapro version in 5, 10 and 20 milligram doses.Behind Pfizer’s Zoloft, Lexapro was the number No. 2 selling antidepressant in US in 2005, according to IMS Health figures, with US sales reaching approximately $2.1 billion last year. The FDA has approved Centocor’s Remicade (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. This approval establishes Remicade as the first and only biologic therapy approved for the treatment of pediatric Crohn's disease. Remicade was first approved in the US as a treatment for adult CD in 1998.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.